PartnershipJun 30, 2026, 08:31 AM
Microbot Medical Partners Sanmina for LIBERTY System Manufacturing
AI Summary
Microbot Medical Inc. has signed a Letter of Agreement with Sanmina Corporation, a global integrated manufacturing solutions provider, to manufacture its LIBERTY Endovascular Robotic System. This partnership aims to expand manufacturing capacity to meet increasing demand in the U.S. and international markets, including recent clearance in Israel and progress towards CE Mark. The company expects the agreement to improve operating efficiencies, lower costs, and expand gross margins, while also providing a second manufacturing site.
Key Highlights
- Microbot Medical entered a Letter of Agreement with Sanmina Corporation for manufacturing its LIBERTY System.
- Sanmina will serve as a second manufacturing site, diversifying capabilities.
- The partnership aims to improve operating efficiencies, lower costs, and expand gross margins.
- It is expected to meet rising demand in the U.S. and international markets.
- Sanmina's global presence could facilitate future production scaling.
- The LIBERTY System is the only FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures.
Price Impact
More from MBOT